Konotey-AhuluFI.Hereditary qualitative and quantitative erythrocyte defects in Ghana: an historical and geographical survey. Ghana Med J1968; 7: 118–119.
2.
HerrickJB.Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Arch Intern Med1910; 6: 517–521.
3.
ConleyCL.Sickle-cell anemia—the first molecular disease. In: WintrobeMM (ed.) Blood, pure and eloquent. New York, NY: McGraw Hill, 1980, pp.319–372.
4.
WareREde MontalembertMTshiloloL, et al. Sickle cell disease. Lancet2017; 390(10091): 311–323.
5.
RosaRMBiererBEThomasR, et al. A study of induced hyponatremia in the prevention and treatment of sickle-cell crisis. N Engl J Med1980; 303(20): 1138–1143.
6.
BrugnaraCde FranceschiLAlperSL.Inhibition of Ca(2+)-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. J Clin Invest1993; 92(1): 520–526.
7.
StamatoyannopoulosGWoodWGPapayannopoulouT, et al. A new form of hereditary persistence of fetal hemoglobin in blacks and its association with sickle cell trait. Blood1975; 46(5): 683–692.
8.
AtwehGFSuttonMNassifI, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood1999; 93(6): 1790–1797.
9.
LeyTJDeSimoneJNoguchiCT, et al. 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood1983; 62(2): 370–380.
10.
CharacheSTerrinMLMooreRD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med1995; 332(20): 1317–1322.
11.
AultA.US FDA approves first drug for sickle-cell anaemia. Lancet1998; 351(9105): 809.
12.
MeansRT.New agents for sickle cell disease: patient perceptions of benefit in the real world. J Investig Med2022; 70(5): 1210–1211.
13.
AliMAAhmadAChaudryH, et al. Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials. Exp Hematol2020; 92: 11–18.e1.
14.
HowardJAtagaKIBrownRC, et al. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol2021; 8(5): e323–e333.
15.
KanterJWaltersMCKrishnamurtiL, et al. Biologic and clinical efficacy of LentiGlobin for sickle cell disease. N Engl J Med2022; 386(7): 617–628.
16.
FrangoulHAltshulerDCappelliniMD, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med2021; 384(3): 252–260.
17.
BenzEJJrSilbersteinLEPanepintoJ.“Treatment with curative intent”: the emergence of genetic therapies for sickle cell anemia. Blood2024; 143(11): 967–970.
18.
GoyalSTisdaleJSchmidtM, et al. Acute myeloid leukemia case after gene therapy for sickle cell isease. N Engl J Med2022; 386(2): 138–147.
19.
StonestromAJLevineRL.The hematopoietic saga of clonality in sickle cell disease. J Clin Invest2022; 132(5): e158251.
